Research / TCBX / Fundamental state Inspectable configuration
State dimensions Filing 0001193125-26-091656 Bank
Sequential deposit growth 56th Own-history percentile · N=16
Evidence method Sequential · gp.financial.deposits
5.81% · CORE · VALID
Net-income growth 31th Own-history percentile · N=13
Evidence method Yoy · gp.fundamentals.net_income
39.06% · CORE · VALID
Cash and equivalents 18th Own-history percentile · N=17
Evidence method Level · gp.fundamentals.cash
$175.2M · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 19 states Self-history eligible
Dec 31, 2021 0/3 normalized Level 3 Mar 31, 2022 0/3 normalized Level 3 Jun 30, 2022 0/3 normalized Level 3 Sep 30, 2022 0/5 normalized Level 3 Dec 31, 2022 0/5 normalized Level 3 Mar 31, 2023 0/5 normalized Level 3 Jun 30, 2023 0/5 normalized Level 3 Sep 30, 2023 1/5 normalized Level 3 Dec 31, 2023 3/5 normalized Level 3 Mar 31, 2024 3/5 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 3/3 normalized Level 3 Dec 31, 2024 3/3 normalized Level 3 Mar 31, 2025 3/3 normalized Level 3 Jun 30, 2025 3/3 normalized Level 3 Sep 30, 2025 3/3 normalized Level 3 Dec 31, 2025 3/3 normalized Level 3 Mar 31, 2026 3/3 normalized Level 3 Jun 30, 2026 3/3 normalized Level 4 Period transition
What moved in the state? Deposit Growth Increased
Previous 2.15%
Current 5.81%
Delta 3.67% Earnings Growth Decreased
Previous 41.35%
Current 39.06%
Delta -2.29% Liquidity Increased
Previous $116.4M
Current $175.2M
Delta $58.8M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.